NDAORALTABLET
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
COREG (carvedilol) by Viatris is adrenergic alpha-antagonists [moa]. First approved in 1995.
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COREG (carvedilol) is an oral alpha-adrenergic blocker approved in 1995 for cardiovascular indications, primarily heart failure and hypertension. It works by blocking alpha-1 and beta-adrenergic receptors, reducing heart workload and blood pressure. The drug is a foundational therapy in cardiology with decades of clinical evidence.
$0.587MPart D
LOE ApproachingDeclining
This mature product faces significant generic competition (30% pressure) and declining Part D utilization, signaling a shrinking brand team focused on market defense rather than growth initiatives.
Mechanism of Action
Adrenergic alpha-Antagonists
Pharmacologic Class:
alpha-Adrenergic Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
Started Oct 2026
28 enrolled
Ovarian Cancer
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.
Started May 2026
442 enrolled
Nasopharyngeal Carcinoma
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
Started Apr 2026
25 enrolled
Cancer
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Started Aug 2025
15 enrolled
HPV-Associated Cervical CarcinomaHPV-Related CarcinomaHPV-Related Malignancy+14 more
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Started May 2025
580 enrolled
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Worked on COREG at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.